Verona Pharma (VRNA)
48.51
1.82 (3.90%)
At close: Jan 14, 2025, 3:59 PM
48.01
-1.04%
After-hours Jan 14, 2025, 07:46 PM EST
undefined% (undefined)
| Bid | 45.8 |
| Market Cap | 3.97B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.06 |
| PE Ratio (ttm) | -23.55 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 49.5 |
| Volume | 1,708,165 |
| Avg. Volume (20D) | 1,095,693 |
| Open | 46.90 |
| Previous Close | 46.69 |
| Day's Range | 46.61 - 49.65 |
| 52-Week Range | 11.39 - 51.80 |
| Beta | undefined |
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 28, 2017
Employees 79
Stock Exchange NASDAQ
Ticker Symbol VRNA
Website https://www.veronapharma.com
Analyst Forecast
According to 7 analyst ratings, the average rating for VRNA stock is "Buy." The 12-month stock price forecast is $44, which is a decrease of -9.30% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Verona Pharma is scheduled to release its earnings on Feb 27, 2025,
before market opens.
Analysts project revenue of $4.93M, reflecting a n/a YoY growth and earnings per share of -0.45, making a 150.00% increase YoY.
Analysts project revenue of $4.93M, reflecting a n/a YoY growth and earnings per share of -0.45, making a 150.00% increase YoY.
1 week ago ·
Source
+10.58%
Verona Pharma shares are trading higher following ...
Unlock content with
Pro Subscription
2 months ago ·
Source
+9.06%
Verona Pharma shares are trading higher after the company reporter better-than-expected Q3 financials.
